1-9 of 9
Patrick P. Ng
Close
Sort by
Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan
Journal: Blood
Blood (2022) 140 (Supplement 1): 7284–7285.
https://doi.org/10.1182/blood-2022-159665
Published: 2022
Journal Articles

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

Patrick P Ng, Wade Aaron, Evan Callihan, Golzar Hemmati, Che-Leung Law, Abdel Kareem Azab, Laura Sun
Journal: Blood
Blood (2021) 138 (Supplement 1): 1185.
https://doi.org/10.1182/blood-2021-151880
Published: 2021
Journal Articles

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

V. Koneti Koneti Rao, MD FRCPA, Patrick P. Ng, PhD, Craig M. Hill, PhD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-137631
Published: 2020
Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1571.
https://doi.org/10.1182/blood-2019-127338
Published: 2019
Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD
Journal: Blood
Blood (2015) 126 (23): 3998.
https://doi.org/10.1182/blood.V126.23.3998.3998
Published: 2015
Journal Articles

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)–infected patients rarely react with the viral proteins

Brief Report
Patrick P. Ng, Chiung-Chi Kuo, Stanley Wang, Shirit Einav, Luca Arcaini, Marco Paulli, Carol S. Portlock, Joseph Marcotrigiano, Alexander Tarr, Jonathan Ball, Ronald Levy, Shoshana Levy
Journal: Blood
Blood (2014) 123 (10): 1512–1515.
https://doi.org/10.1182/blood-2013-10-532895
Published: 2014
Journal Articles

Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy

James A Torchia, Patrick P Ng, PhD, Homer Chen, Holbrook E Kohrt, MD, PhD, Aurelien Marabelle, MD, MSc, Ash A. Alizadeh, MD, PhD, Ronald Levy, MD
Journal: Blood
Blood (2012) 120 (21): 3713.
https://doi.org/10.1182/blood.V120.21.3713.3713
Published: 2012
Journal Articles

Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma.

Patrick P. Ng, Ming Jia, Alejandro Virrueta, Kedar Patel, James R. Swartz, Shoshana Levy, Ronald Levy
Journal: Blood
Blood (2009) 114 (22): 2712.
https://doi.org/10.1182/blood.V114.22.2712.2712
Published: 2009
Journal Articles

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor

Patrick P. Ng, Gustavo Helguera, Tracy R. Daniels, Simon Z. Lomas, Jose A. Rodriguez, Gary Schiller, Benjamin Bonavida, Sherie L. Morrison, Manuel L. Penichet
Journal: Blood
Blood (2006) 108 (8): 2745–2754.
https://doi.org/10.1182/blood-2006-04-020263
Published: 2006
Includes: Supplemental data